ClinicalTrials.gg
Active, not recruitingNCT04305613CLARITYUpdated Oct 5, 2026

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

An observational study in Cardiotoxicity, Lung Cancer Stage III and Lung Cancer Stage II, sponsored by Abramson Cancer Center at Penn Medicine. Active, not recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Abramson Cancer Center at Penn Medicine · Observational

How we know

Updated Oct 5, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
221
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Cardiotoxicity by Abramson Cancer Center at Penn Medicine — 1 open to participants now, 5 under way, none of them phase 3. Cardiotoxicity · Abramson Cancer Center at Penn Medicine.

Started
2020
with 1 other
Observational
8 of 10
1 open now
Registered
4th of 10
by date

Among the 10 studies in Cardiotoxicity by Abramson Cancer Center at Penn Medicine, this one is one of 2 that started in 2020, is one of 8 observational ones, and was the 4th registered.

Cardiotoxicity

263 studies on the registry are indexed under Cardiotoxicity; 76 are open to participants now.

Browse Cardiotoxicity studies →

Open to participants now

1 of the 10 studies in Cardiotoxicity by Abramson Cancer Center at Penn Medicine is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 51 Cardiotoxicity studies recruiting now, 38 (75%) set no upper age limit and 8 (16%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cardiotoxicity by Abramson Cancer Center at Penn Medicine, or all of them as a file.
02

Study summary

This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tests, blood sampling, and quality of life surveys.

Read the detailed description

Lung cancer is both the most common malignancy worldwide and the leading cause of cancer death in the US. While radiation therapy is highly effective for many solid tumors, thoracic radiation therapy carries a risk of cardiovascular morbidity and mortality that limits critical gains in cancer control and survival. The investigators will perform detailed cardiovascular phenotyping using biologic and imaging markers to define functional and physiologic perturbations that occur with radiation therapy. The study will provide insights into how cardiovascular risk factors and disease impact these biologic and functional changes. The investigators will also determine which radiotherapy dose-volume metrics are indicative of subclinical cardiotoxicity.

03

Conditions studied

  • Cardiotoxicity
  • Lung Cancer Stage III
  • Lung Cancer Stage II
  • Radiation Toxicity

Keywords

  • Radiation Therapy Cardiotoxicity
  • Cardiovascular Risk Factors
  • Lung Cancer
  • Cardiovascular Phenotyping
  • Radiation Therapy
  • Cardiovascular Disease
  • Cardio-Oncology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with lung cancer will be enrolled from the radiation oncology clinics at participating sites.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • confirmed or clinically diagnosed non-small cell lung cancer where the plan is for definitive treatment that includes radiation
  • Able to give written

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding
  • Prior treatment with anthracyclines
  • Radiation treatment not expected to involve any heart exposure as determined by treating provider
  • performance status greater than 2
  • Vulnerable patients, including pregnant women and prisoners
  • to rest/vasodilator stress PET/CT, including: asthma with ongoing wheezing at time of enrollment; known Mobitz Type II AV block, 3rd degree AV block, or sick sinus syndrom, without a pacemaker; systolic blood pressure less than 90mmHg; known to Regadenoson and adenosine; profound sinus bradycardia (heart rate less than 40bpm).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
221 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort

    Patients with locally advanced non-small cell lung cancer

    Other: Chemoradiation

Interventions

  • OtherChemoradiation

    Patients will be treated with definitive concurrent chemoradiation with curative intent as determined by their medical and radiation oncologists. We will consider timing of initiation and discontinuation, type, and cumulative dose of platinum based chemotherapy. We will also consider dose, duration, and type of immunotherapy. Radiation therapy will be delivered via proton or proton therapy. Our primary radiation therapy dose-volume exposures are whole heart volumetric dose. As secondary exposures, we will comprehensively define radiation therapy dose parameters to the right ventricle, entire left ventricle, left ventricle segments, coronary arteries, and mean heart dose.

06

What researchers measure

Primary outcomes

  1. High Sensitivity C-Reactive Protein

    Change in hsCRP from baseline

    Time frame: up to 12 months

  2. Growth Differentiation Factor 15

    Change in GDF-15 from baseline

    Time frame: up to 12 months

  3. Placental Growth Factor

    Change in PIGF from baseline

    Time frame: up to 12 months

  4. Left Ventricular Strain

    Change in echo-derived measures of LV peak systolic strain (longitudinal) from baseline

    Time frame: up to 12 months

  5. Ventricular Arterial Coupling

    Change in echo-derived measures of ventricular-arterial coupling (Ea/Ees) from baseline

    Time frame: up to 12 months

  6. Coronary Flow Reserve (CFR_

    Change in PET/CT derived CFR from baseline

    Time frame: 6 months

  7. Overall Survival (2 Year)

    All-cause mortality assessed by electronic medical record (EMR) review

    Time frame: 24 months

  8. Cardiovascular Specific Mortality (2 Year)

    Cardiovascular specific mortality assessed by EMR review

    Time frame: 24 Months

  9. Major Cardiovascular Events (2 Year)

    Incidence of MCE assessed by EMR review and patient interview

    Time frame: up to 24 months

Secondary outcomes

  1. High-Sensitivity Troponin T

    Change in hsTnT from baseline

    Time frame: up to 12 months

  2. N-type pro Brain Natriuretic Peptide

    Change in NTproBNP from baseline

    Time frame: up to 12 months

  3. Left Ventricular Ejection Fraction (2D)

    Change in echo-derived LVEF from baseline

    Time frame: up to 12 months

  4. Right Ventricular Fractional Area Change (RAC)

    Change in echo-derived RAC from baseline

    Time frame: up to 12 months

  5. Right Ventricular Longitudinal Strain

    Change in echo-derived RV longitudinal strain from baseline

    Time frame: up to 12 months

  6. Circumferential Strain

    Change in echo-derived circumferential strain from baseline

    Time frame: up to 12 months

  7. Diastolic Function

    Change in echo-derived measures of diastolic function from baseline

    Time frame: up to 12 months

  8. Valvular Disease

    Change in echo-derived measures of valvular disease (degree of regurgitation or stenosis) from baseline

    Time frame: up to 12 months

  9. Left Ventricular Ejection Fraction (3D)

    Change in 3D echocardiography derived LVEF from baseline

    Time frame: up to 12 months

  10. Left Ventricular systolic strain (3D)

    Change in 3D echocardiography derived measures of LV systolic strain from baseline

    Time frame: up to 12 months

  11. Left Ventricular Twist and Torsion

    Change in 3D echocardiography derived measures of LV twist and torsion from baseline

    Time frame: up to 12 months

  12. Global and Regional Myocardial Blood Flow at Rest

    Change in PET/CT derived measures of global and regional myocardial blood flow at rest from baseline

    Time frame: up to 6 months

  13. Global and Regional Myocardial Blood Flow at Stress

    Change in PET/CT derived measures of global and regional myocardial blood flow at stress from baseline

    Time frame: up to 6 months

  14. FACIT Fatigue Score

    Change in FACIT Fatigue score from baseline. Score ranges from 0-52. Higher scores indicated less fatigue.

    Time frame: up to 5 years

  15. FACIT Dyspnea Score

    Change in FACIT Dyspnea score from baseline. Score ranges from 0-30. Higher scores indicate more dyspnea.

    Time frame: up to 5 years

  16. Godin Leisure Time Exercise Score

    Change in Godin Leisure Time Exercise Score from baseline. Higher scores indicate higher levels of physical activity.

    Time frame: up to 5 years

Other outcomes

  1. Overall Survival (5 Year)

    All Cause Mortality assessed by National Death Index Search performed 5 years after the last patient is enrolled.

    Time frame: 5-8 years

  2. Cardiovascular Specific Mortality (5 Year)

    Cardiovascular Specific Mortality by National Death Index Search performed approximately 5 years after the final patient is enrolled.

    Time frame: 5-8 Years

  3. Major Cardiovascular Events (5 Year)

    Incidence of 5-Year MCE by EMR review and patient interview

    Time frame: 5 years

  4. NCI Patient Reported Outcomes Common Terms and Criteria for Adverse Events (PRO-CTCAE)

    Incidence of symptomatic adverse events as assessed by NCI's PRO-CTCAE

    Time frame: 5 Years

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: Undecided — Participants may opt in to allowing data and/or banked samples to be used for future research and shared with other researchers. A detailed plan for sharing IPD will be finalized at a later date, and may depend in part on how many participants elect this option. Additional supporting information may be shared, including the study protocol and informed consent form.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Dec 2026, 75 months after the start.

Of 69 non-industry observational studies under Cardiotoxicity, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 122. This study's planned 75 months is close to that.

Counting every sponsor, half of 71 studies reached it within 69 months; a quarter within 33 and three quarters within 122.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2020
First posted
Mar 12, 2020
StartActual
Sep 14, 2020
Primary completionEst.
Dec 2026was Sep 2026
CompletionEst.
Dec 2030
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Dec 2026
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Primary completion Sep 2026→Dec 2026
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04305613
Responsible party
Sponsor
First posted
Mar 12, 2020
Start date
Sep 14, 2020
Primary completion
Dec 2026 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 5, 2026

Study contacts

Bonnie Ky, MD, MSCE
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion